Welcome to our dedicated page for Motus Gi Hldgs news (Ticker: MOTS), a resource for investors and traders seeking the latest updates and insights on Motus Gi Hldgs stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Motus Gi Hldgs's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Motus Gi Hldgs's position in the market.
Motus GI Holdings announces the launch of a new mobile app providing physicians and hospitals on-demand access to support and educational resources for the Pure-Vu® System. The app enhances the engagement with hospitals, particularly during the COVID-19 pandemic, offering training resources like videos, tutorials, and case studies. The Pure-Vu System, FDA-cleared, aims to improve colonoscopy outcomes through better visualization. It has achieved bowel cleanliness rates exceeding 95% in clinical studies, serving a significant unmet need in gastrointestinal procedures.
Motus GI Holdings, Inc. (NASDAQ: MOTS) will present at the Virtual Investor Fireside Chat Series on June 15, 2020, at 2:00 PM ET. Timothy P. Moran, CEO, will discuss the company’s endoscopy solutions aimed at improving gastrointestinal diagnosis. The session includes a live Q&A, allowing real-time engagement with participants. A replay will be available after the event. The company’s flagship product, the Pure-Vu® System, enhances colonoscopy procedures, aiming to improve patient outcomes and reduce costs for hospitals. More information can be found on the company’s website.
Motus GI Holdings, Inc. (NASDAQ: MOTS) reported first-quarter 2020 results, highlighting a net loss of approximately $6.5 million, or $0.23 per diluted share. Despite challenges from the COVID-19 pandemic affecting inpatient colonoscopies, the company has successfully placed the Pure-Vu® System in 19 major U.S. hospitals since its launch, training over 75 GI physicians. A key regulatory achievement, CE mark approval for the GEN2 Pure-Vu® System, opens potential European markets. Cash resources totaled $21.5 million, sufficient to meet obligations into late 2020.
Motus GI Holdings, Inc. has received a new patent (No. 10646108) from the U.S. Patent and Trademark Office, which safeguards its Pure-Vu® System, enhancing endoscopy procedures by improving colon visualization. The Pure-Vu System integrates with standard colonoscopes, facilitating better bowel preparation during colonoscopies, particularly crucial for patients with medical complexities. This innovation addresses significant unmet needs in gastrointestinal care, potentially leading to cost savings and better clinical outcomes, with over 95% success in bowel cleanliness in clinical studies.
Motus GI Holdings, Inc. (NASDAQ: MOTS) will announce its Q1 2020 financial results on May 14, 2020, following market close. A conference call will occur at 4:30 p.m. ET to discuss the results and corporate updates. Motus GI specializes in endoscopy solutions aimed at improving clinical outcomes and cost-efficiency in gastrointestinal conditions, featuring the Pure-Vu® System. This device assists in cleaning poorly prepared colons, potentially enhancing colonoscopy quality amidst over 1.5 million annual procedures in the U.S.